Oncolytics Biotech (ONCY) investor relations material

Executive summary

• Focused on advancing pelareorep, an immunotherapeutic agent, for GI cancers, with ongoing and planned registration-enabling clinical studies in metastatic colorectal, anal, and pancreatic cancers.

• Received Fast Track Designation for pelareorep in combination therapies for both metastatic colorectal cancer and squamous cell carcinoma of the anal canal in 2026.

• Completed domestication to Nevada and expanded intellectual property portfolio, including a new U.S. patent for manufacturing processes.

Financial highlights

• Net loss for Q2 2026 was $9.4 million, up from $5.3 million in Q2 2025; six-month net loss was $18.7 million, up from $10.0 million year-over-year.

• R&D expenses rose to $4.3 million in Q2 2026 from $1.9 million in Q2 2025, driven by clinical trial start-up and increased personnel costs.

• G&A expenses increased to $5.1 million in Q2 2026 from $2.7 million in Q2 2025, reflecting higher investor relations, legal, and stock-based compensation costs.

• Cash and cash equivalents were $4.1 million as of June 30, 2026, compared to $5.2 million at year-end 2025.

• Raised $14.4 million net from ATM equity offerings in the first half of 2026.

Outlook and guidance

• Current cash resources are sufficient for near-term milestones but not for at least twelve months of planned operations; additional financing is required.

• Ongoing focus on advancing second-line mCRC and SCAC programs, manufacturing readiness, and strategic partnerships.

• Plans to continue utilizing ATM equity programs and seek strategic collaborations.